Myriad Genetics Intrinsic Value – Myriad Genetics’ Weekly Ratings Receive Analysts’ Attention
December 30, 2023
🌥️Trending News
Analysts have been paying close attention to the weekly ratings changes for Myriad Genetics ($NASDAQ:MYGN), Inc. The publicly traded biotechnology company focuses on developing and marketing novel molecular diagnostic products. The company is committed to advancing its molecular diagnostics and personalized medicine capabilities, and it provides testing for genetic-based diseases and other complex disorders. Myriad Genetics’ portfolio of molecular diagnostics provides a comprehensive line of products that aids in the identification, diagnosis, and monitoring of many serious medical conditions. Its products include an array of tests for cancer, genetics-associated disease, hereditary cancer risk assessment, and maternal-fetal medicine. With its comprehensive suite of advanced genetic testing solutions, Myriad Genetics is well-positioned to continue to drive the development and adoption of personalized medicine across a wide range of medical indications.
The company’s stock price has been steadily increasing over the past year, and analysts have been closely following its progress. This is largely due to the company’s ability to continually innovate and bring new products to market. The analysts’ weekly ratings changes for Myriad Genetics have been consistently positive, underscoring the company’s potential for long-term growth and profitability. As such, Myriad Genetics remains an attractive investment option for investors seeking exposure to the growing biotechnology sector.
Price History
Analysts have been paying close attention to Myriad Genetics‘ performance this week. On Thursday, the company’s stock opened at $19.7 and closed at the same price, down by 0.3% from its prior closing price of $19.8. There was a lack of significant activity in the stock throughout the day with no major news announcements or developments that could explain the slight decrease in price. Analysts are keeping an eye on Myriad Genetics to see how their stock performs in the coming days and weeks. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Myriad Genetics. More…
| Total Revenues | Net Income | Net Margin |
| 734.4 | -274.4 | -36.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Myriad Genetics. More…
| Operations | Investing | Financing |
| -63.5 | 8.3 | 28.9 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Myriad Genetics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.15k | 465.7 | 8.31 |
Key Ratios Snapshot
Some of the financial key ratios for Myriad Genetics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -1.2% | -62.6% | -38.0% |
| FCF Margin | ROE | ROA |
| -18.8% | -24.6% | -15.2% |
Analysis – Myriad Genetics Intrinsic Value
At GoodWhale, we have performed an analysis of MYRIAD GENETICS‘ fundamentals and have determined the fair value of MYRIAD GENETICS’ share to be around $22.6. This figure was calculated using our proprietary Valuation Line. Although this is the fair price, we see that MYRIAD GENETICS stock is currently being traded at $19.7 – a price that is undervalued by 12.6%. More…
Peers
Myriad Genetics Inc is facing intense competition from BCAL Diagnostics Ltd, Inoviq Ltd, and Exagen Inc in the field of molecular diagnostics. Each of these companies offers innovative products and services, and is striving to gain a competitive edge in the market. As a result, Myriad Genetics Inc is under constant pressure to develop and deliver better products to stay ahead of the competition.
– BCAL Diagnostics Ltd ($ASX:BDX)
Inoviq Ltd is a leading provider of medical and healthcare products. Its market cap of 59.81M as of 2022 indicates that the company is growing steadily and is well-positioned in the market. Its Return on Equity (ROE) of -13.77% suggests that the company is making investments that have yet to yield a positive return. The company’s goal is to continue to develop innovative products and services that will improve patient outcomes and enhance the quality of life. Inoviq Ltd is a leader in the medical and healthcare industry and its market cap and ROE are both indicators of its success.
– Inoviq Ltd ($ASX:IIQ)
Exagen Inc is a biotechnology company that focuses on developing and commercializing diagnostic and therapeutic products for autoimmune diseases. The company’s market cap as of 2022 is 39.49M, which means that the value of the company is determined by the current market price of its shares. The Return on Equity (ROE) is -38.89%, indicating that the company is not generating a return on investments it made in its business operations. This suggests that the company may need to reevaluate its strategies in order to become more profitable and increase shareholder value.
Summary
Myriad Genetics Inc. (MYGN) has been the subject of recent analyst ratings changes. Several analysts have recently given the company ratings changes, ranging from upgrades to downgrades to price targets. Most of the analyst ratings changes appear to be bullish, with several of the upgrades coming from investment firms such as Deutsche Bank, JPMorgan Chase & Co., and Jefferies. These analysts have noted that they are encouraged by Myriad Genetics’ strong product pipeline and potential for new opportunities in the healthcare and diagnostic markets.
Additionally, they have praised the company’s cost containment initiatives and focus on audience segmentation to increase sales and margins. Overall, the analyst ratings changes point to the potential for Myriad Genetics’ stock to rise in the future.
